RESEARCH TRIANGLE PARK, N.C. – May 18, 2010 – Quintiles, the only fully integrated bio pharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, and Kaiser Permanente’s Southern California Permanente Medical Group (SCPMG) today announced an agreement to help accelerate the development of new and more effective medicines.

Southern California Permanente Medical Group will join Quintiles’ three other prime sites globally, selected for their long-term commitment to clinical research.  Clinical research professionals from both Quintiles and SCPMG will work together closely to enhance the productivity and quality of clinical research offered at the SCPMG site. Bio pharmaceutical companies sponsoring trials will benefit from greater collaboration between clinicians and research professionals, and robust processes for reducing complexity and accelerating trials.

Adam Chasse, Head of Global Prime Sites at Quintiles explains, “Quintiles undertakes more clinical research than any other organization, and that is why our customers rely on us to help them navigate risk and seize opportunity in this new landscape we call the New Health. It is therefore critical that we develop alliances with healthcare providers that share our focus on developing new and better medicines while keeping patient care at the forefront. Kaiser Permanente’s rich background in clinical, epidemiologic, and translational research is a natural fit with Quintiles’ core capabilities.”

Donald S. Fong, MD, MPH, Director of Clinical Trials, SCPMG Department of Research & Evaluation, Kaiser Permanente Southern California says, “The Southern California Permanente Clinical Trials program works on the premise that all clinical trials research should focus on advancing the practice of medical care to improve health outcomes through rigorously designed and executed trials.

“Southern California Permanente Clinical Trial investigators are practicing physicians who use their clinical acumen and methodological training to bridge the gap between basic research and clinical practice. Typically, clinical trials research in Kaiser Permanente is aimed at evaluating the impact of interventions at the bedside. This perspective ensures that trials address meaningful questions.” Quintiles other prime sites are at the University of Pretoria in South Africa, Queen Mary’s College in London, UK and the Washington Hospital Center in Washington DC, USA.

About Quintiles

Quintiles is the only fully integrated bio pharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bio pharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.